Neuroleptic Properties of Cis-N-(1-benzyl-2-methylpyrrolidin-3-yl)-5-chloro-2-methoxy-4-methylaminobenzamide (YM-09151-2) with Selective Antidopaminergic Activity

Overview

Journal Psychopharmacology (Berl)

Specialty Pharmacology

Date 1981 Jan 1

PMID 6112770

Citations 12

Authors

S Usuda

K Nishikori

O Noshiro

H Maeno

Affiliations

Soon will be listed here.

Abstract

A new benzamide, cis-N-(1-benzyl-2-methylpyrrolidin - 3 - yl) - 5 - chloro - 2 - methoxy - 4 - methylaminobenzamide (YM-09151-2) exhibited more potent and longer-lasting inhibitory effects on apomorphine-induced behaviours (stereotyped behaviour, emesis and hypothermia), and methamphetamine-induced stereotyped behaviour, conditioned avoidance response and open field behaviour, conditioned avoidance response and open field behaviour than either structurally similar benzamides (YM-0850 and sulpiride) or classical neuroleptics [chlorpromazine (CPZ) and haloperidol(HPD)]. Such inhibitory effects of YM-09151-2 relative to cataleptogenicity were greater than those of CPz and HPD. In contrast, sulpiride elicited few of the neuroleptic effects described above. YM-09151-2, a potent inhibitor for dopamine-sensitive adenylate cyclase (Ki: 3.0 nM) reduced, in a selective manner, the binding of [3H]dopamine to the dopamine D1 receptor (Ki:4.8 nm) associated with adenylate cyclase rather than to the dopamine D2 receptor (Ki: 0.98 microM) independent of adenylate cyclase. Sulpiride, on the contrary, inhibited only the binding to the dopamine D2 receptor, CPZ and HPD antagonized [3H]dopamine nonselectively at the two distinct dopaminergic receptors. These results suggest that YM-09151-2 is a potent and long-lasting neuroleptic with a highly selective blocking action on the dopamine D1 receptor.

Citing Articles

The Behavioral and Pharmacological Actions of NMDA Receptor Antagonism are Conserved in Zebrafish Larvae.

Chen J, Patel R, Friedman T, Jones K Int J Comp Psychol. 2011; 23(1):82-90.

PMID: 21278812 PMC: 3027073.

Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability.

Bishara D, Taylor D Drugs. 2008; 68(16):2269-92.

PMID: 18973393 DOI: 10.2165/0003495-200868160-00002.

In vitro pharmacological profile of YM-43611, a novel D2-like receptor antagonist with high affinity and selectivity for dopamine D3 and D4 receptors.

Hidaka K, Tada S, Matsumoto M, Ohmori J, Tasaki Y, Nomura T Br J Pharmacol. 1996; 117(8):1625-32.

PMID: 8732269 PMC: 1909569. DOI: 10.1111/j.1476-5381.1996.tb15332.x.

Dopamine receptors in canine caudate nucleus.

Maeno H Mol Cell Biochem. 1982; 43(2):65-80.

PMID: 6123940 DOI: 10.1007/BF00423094.

Enhancement by a single dose of reserpine (plus alpha methyl-p-tyrosine) of the central stimulatory effects evoked by dopamine D-1 and D-2 agonists in the mouse.

Ross S, Jackson D, Wallis E, Edwards S Naunyn Schmiedebergs Arch Pharmacol. 1988; 337(5):512-8.

PMID: 3261844 DOI: 10.1007/BF00182724.

References

Costall B, Funderburk W, Leonard C, Naylor R . Assessment of the neuroleptic potential of some novel benzamide, butyrophenone, phenothiazine and indole derivatives. J Pharm Pharmacol. 1978; 30(12):771-8. DOI: 10.1111/j.2042-7158.1978.tb13390.x. View

Cools A, van Rossum J . Excitation-mediating and inhibition-mediating dopamine-receptors: a new concept towards a better understanding of electrophysiological, biochemical, pharmacological, functional and clinical data. Psychopharmacologia. 1976; 45(3):243-54. DOI: 10.1007/BF00421135. View

Brown B, Ekins R, Albano J . Saturation assay for cyclic AMP using endogenous binding protein. Adv Cyclic Nucleotide Res. 1972; 2:25-40. View

Laville C, Margarit J . [The effects of sulpiride on the central nervous system]. Pathol Biol (Paris). 1969; 17(1):71-5. View

Elliott P, Jenner P, Huizing G, Marsden C, Miller R . Substituted benzamides as cerebral dopamine antagonists in rodents. Neuropharmacology. 1977; 16(5):333-42. DOI: 10.1016/0028-3908(77)90070-3. View

Spano P, Govoni S, Trabucchi M . Studies on the pharmacological properties of dopamine receptors in various areas of the central nervous system. Adv Biochem Psychopharmacol. 1978; 19:155-65. View

Jenner P, Clow A, Reavill C, Theodorou A, Marsden C . A behavioural and biochemical comparison of dopamine receptor blockade produced by haloperidol with that produced by substituted benzamide drugs. Life Sci. 1978; 23(6):545-9. DOI: 10.1016/0024-3205(78)90032-2. View

Creese I, Burt D, Snyder S . Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science. 1976; 192(4238):481-3. DOI: 10.1126/science.3854. View

Rotrosen J, WALLACH M, Angrist B, Gershon S . Antagonism of apomorphine-induced sterotypy and emesis in dogs by thioridazine, haloperidol, and pimozide. Psychopharmacologia. 1972; 26(2):185-94. DOI: 10.1007/BF00422105. View

10.

Kebabian J, Calne D . Multiple receptors for dopamine. Nature. 1979; 277(5692):93-6. DOI: 10.1038/277093a0. View

11.

Janssen P, NIEMEGEERS C, SCHELLEKENS K . IS IT POSSIBLE TO PREDICT THE CLINICAL EFFECTS OF NEUROLEPTIC DRUGS (MAJOR TRANQUILLIZERS) FROM ANIMAL DATA?I. "NEUROLEPTIC ACTIVITY SPECTRA" FOR RATS. Arzneimittelforschung. 1965; 15:104-17. View

12.

Sano K, Noshiro O, Katsuda K, Nishikori K, Maeno H . Dopamine receptors and dopamine-sensitive adenylate cyclase in canine caudate nucleus. Characterization and solubilization. Biochem Pharmacol. 1979; 28(24):3617-27. DOI: 10.1016/0006-2952(79)90408-8. View

13.

Usuda S, Sano K, Maeno H . Pharmacological and biochemical studies on a new potential neuroleptic, N-(1-benzyl-3-pyrrolidinyl)-5-chloro-2-methoxy-4-methylaminobenzamide (YM-08050). Arch Int Pharmacodyn Ther. 1979; 241(1):68-78. View

14.

Nishikori K, Noshiro O, Sano K, Maeno H . Characterization, solubilization, and separation of two distinct dopamine receptors in canine caudate nucleus. J Biol Chem. 1980; 255(22):10909-15. View

15.

Di Chiara G, Corsini G, Mereu G, TISSARI A, Gessa G . Self-inhibitory dopamine receptors: their role in the biochemical and behavioral effects of low doses of apomorphine. Adv Biochem Psychopharmacol. 1978; 19:275-92. View

16.

Borenstein P, Cujo P, Champion C, Olivenstein C . [Study of a new psychotropic agent: sulpiride (1403 RD). I. Method and clinical results]. Ann Med Psychol (Paris). 1968; 2(1):90-9. View

17.

Puech A, Simon P, BOISSIER J . Benzamides and classical neuroleptics: comparison of their actions using 6 apomorphine-induced effects. Eur J Pharmacol. 1978; 50(4):291-300. DOI: 10.1016/0014-2999(78)90134-6. View

18.

Di Chiara G, Porceddu M, Vargiu L, Argiolas A, Gessa G . Evidence for dopamine receptors mediating sedation in the mouse brain. Nature. 1976; 264(5586):564-7. DOI: 10.1038/264564a0. View

19.

Sano K, Nishikori K, Noshiro O, Maeno H . Reconstitution of dopamine-sensitive adenylate cyclase from dissociated components in canine caudate nucleus. Arch Biochem Biophys. 1979; 197(1):285-93. DOI: 10.1016/0003-9861(79)90247-9. View

20.

LITCHFIELD Jr J, WILCOXON F . A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther. 1949; 96(2):99-113. View